Poland

Ryvu Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

POLAND Poland

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021

Lead Product(s): MEN1703

Therapeutic Area: Oncology Product Name: SEL24

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2021

Details:

In the dose escalation part of DIAMOND-01 trial, SEL24(MEN1703) demonstrated a manageable safety profile up to the recommended dose (RD) of 125 mg/day, along with initial evidence of anti-leukemic activity in a single agent setting.

WPD Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

POLAND Poland

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate

Lead Product(s): Annamycin,Cytarabine

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Polish National Center for Research and Development

Deal Size: $6.7 million Upfront Cash: Undisclosed

Deal Type: Funding May 11, 2021

Details:

Annamycin is a "next generation" anthracycline, that has been shown to be less cardiotoxic compared to other anthracycline, such as doxorubicin, and to avoid multidrug resistance, so the use of Annamycin may not face the same dose limitations imposed on doxorubicin.